🐂 Not all bull runs are created equal. November’s AI picks include 5 stocks up +20% eachUnlock Stocks

agilon health names Karthik Rao as permanent CMO

EditorIsmeta Mujdragic
Published 07/10/2024, 12:08 PM
AGL
-

AUSTIN, Texas - agilon health, inc. (NYSE: AGL), a company partnering with physicians to transform health care, announced the appointment of Karthik Rao, M.D., as its permanent Chief Medical Officer (CMO), effective immediately. Dr. Rao had been serving as the interim CMO since February 2024 and will continue to co-lead the company's clinical strategy alongside Chief Clinical Officer Kevin Spencer, M.D.

Dr. Rao, who joined agilon in 2022, brings a wealth of experience from his previous roles in value-based care and as a practicing internal medicine physician. In his new position, he will oversee the company's clinical programs and network engagement initiatives.

Dr. Spencer, who has over 25 years of experience in value-based care and is a founding partner at agilon, will continue to manage operations and medical directors, aiming to enhance provider performance within agilon's Physician Network.

CEO Steve Sell expressed confidence in the capabilities of both Dr. Rao and Dr. Spencer to advance agilon's mission of empowering physicians and improving care for Medicare patients. Sell highlighted the importance of their roles in supporting the more than 3,000 primary care physicians within agilon's full-risk model to deliver better outcomes.

agilon health is recognized for its partnerships and technology platform that facilitate the transition of physician groups and health systems to a value-based Total Care Model, particularly for senior patients.

The information in this article is based on a press release statement.

In other recent news, agilon health has seen significant changes and developments. The company has appointed Jeff Schwaneke as its new Chief Financial Officer, bringing over 27 years of experience in finance and operations to the role. Schwaneke's appointment comes as agilon health experiences strong demand for its healthcare model.

In financial news, agilon health's Q1 2024 results showed a minor revenue shortfall of 0.6%, but a significant 52% EBITDA beat against consensus, primarily due to reduced operating expenses.

Analysts from RBC Capital Markets and JMP Securities have given positive ratings, while Barclays Capital Inc. has expressed some concerns about the company's future performance. Truist Securities retained a "Hold" rating on the stock, with a slight increase in the price target to $6.50 from $6.40.

Despite exiting certain unprofitable payer contracts, agilon health maintains its full-year guidance for medical margin and adjusted EBITDA. The company's Medicare Advantage membership grew by 43% to 523K, slightly below estimates but within guidance.

These are among the recent developments for agilon health.

InvestingPro Insights

As agilon health, inc. (NYSE: AGL) reinforces its leadership team with the appointment of Dr. Karthik Rao as Chief Medical Officer, the company's financial health and market performance provide a backdrop for evaluating its potential. With a market capitalization of $2.36 billion and a significant revenue growth of 74.48% over the last twelve months as of Q1 2024, agilon's scale in the healthcare sector is evident.

Despite the robust revenue increase, agilon faces challenges with profitability, as reflected in a negative P/E ratio of -8.22 and an adjusted P/E ratio for the last twelve months as of Q1 2024 of -11.8. This suggests that investors are cautious about the company's earnings outlook. Additionally, the company's gross profit margin stands at a modest 1.47%, indicating potential inefficiencies or competitive pressures affecting profitability.

InvestingPro Tips highlight that agilon health holds more cash than debt, suggesting a solid financial position to support its strategic initiatives. Moreover, the management's aggressive share buyback program is a signal that they believe the shares are undervalued, which could be an interesting point for investors to consider. For those interested in exploring more about agilon health's financials and market performance, InvestingPro offers additional tips and insights at: https://www.investing.com/pro/AGL. There are 5 more InvestingPro Tips available, which can provide a deeper understanding of the company's valuation and outlook.

For readers looking to delve further into agilon health's financial details and benefit from comprehensive analysis, use the coupon code PRONEWS24 to get up to 10% off a yearly Pro and a yearly or biyearly Pro+ subscription at InvestingPro. This opportunity not only offers valuable insights into agilon's performance but also equips investors with the information necessary to make informed decisions in a dynamic healthcare market.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.